Future Science Group
Browse
- No file added yet -

Infographic – Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design

Download (1.41 MB)
figure
posted on 2022-01-31, 09:00 authored by Taylor & FrancisTaylor & Francis, Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design

 

Infographic – Summary of the article 

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    BinimetinibBRAFV600 mutationclinical trialefficacyencorafenibnon-small cell lung cancerobjective response ratesafetyCancer Therapy (excl. Chemotherapy and Radiation Therapy)Cancer Genetics

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC